Brain cancers are difficult to treat, and it can be hard to predict whether a therapy will be effective. When the patient is a child, it's even more important to predict the potential effectiveness of a drug before beginning treatment. In this first ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron emission tomography/computed tomography (PET/CT) scans to determine whether bevacizumab (Avastin) treatment of diffuse intrinsic pontine glioma (DIPG) in children is likely to be effective. The study is featured in the May 2017 issue of The Journal of Nuclear Medicine.
"Children with DIPG have a very poor prognosis, with less than 10 percent of the patients surviving two years from diagnosis," explains Guus A. van Dongen, PhD, of VU University, Medical Center, Amsterdam, The Netherlands. "These tumors are resistant to all kinds of therapies. Chemotherapy, as well as new targeted therapies, may not reach the tumor due to the location within the brainstem."
For the study, researchers investigated whether bevacizumab can reach the tumor in children with DIPG by measuring the tumor uptake of zirconium-89 (Zr-89)-labeled bevacizumab with PET. In addition, they evaluated the safety of the procedure and determined the optimal timing of imaging.
Two weeks after completing radiotherapy, seven patients (age range: 6-17) were given whole-body PET/CT scans performed at 1, 72 and 144 hours post-injection. The optimal moment of scanning was found to be 144 hours post-injection. The patients also underwent contrast (gadolinium)-enhanced MRI.
"The results showed that indeed there is considerable heterogeneity in uptake of Zr-89-labeled bevacizumab among patients and within tumors," Van Dongen points out. "This non-invasive in vivo quantification of drug distribution and tumor uptake may help to predict therapeutic potential, as well as toxicity, and could help develop strategies for improving drug delivery to tumors."
Van Dongen adds, "Children with brain tumors and other solid cancers are particularly likely to benefit from molecular drug imaging, as drugs without therapeutic effect--based on a lack of drug-uptake in the tumor--may cause life-long side effects. Molecular drug imaging will open avenues for administering the right drug to the right patient at the most appropriate stage of the disease."
The authors of "Molecular Drug Imaging: 89Zr-bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma" include Marc H. Jansen, Sophie E.M. Veldhuijzen van Zanten, Dannis G. van Vuurden, Marc C. Huisman, Danielle J. Vugts, Otto S Hoekstra, Guus A. van Dongen, and Gert-Jan L. Kaspers, VU University Medical Center, Amsterdam, The Netherlands.
Funding for this study was provided by the Semmy Foundation and Egbers Foundation.
Please visit the SNMMI Media Center to view the PDF of the study, including images, and more information about molecular imaging and personalized medicine. To schedule an interview with the researchers, please contact Laurie Callahan at (703) 652-6773 or email@example.com. Current and past issues of The Journal of Nuclear Medicine can be found online at http://jnm.
About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today's medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.
SNMMI's more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.